Previous close | 0.3450 |
Open | 0.3450 |
Bid | 0.3400 x 1582700 |
Ask | 0.3550 x 3535900 |
Day's range | 0.3370 - 0.3450 |
52-week range | 0.2800 - 0.4800 |
Volume | |
Avg. volume | 40,249 |
Market cap | 49.431M |
Beta (5Y monthly) | 0.61 |
PE ratio (TTM) | N/A |
EPS (TTM) | -0.0280 |
Earnings date | 23 Feb 2023 - 27 Feb 2023 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
The underwhelming share price performance of Cynata Therapeutics Limited ( ASX:CYP ) in the past three years would have...
Cynata Therapeutics Limited (ASX: "CYP" or "Cynata"), a clinical-stage biotechnology company specialising in cell therapeutics, is delighted to announce that the LUMC is funding an important clinical trial to investigate Cynata's Cymerus™ MSCs as a treatment for renal graft rejection and to potentially reduce the requirement for anti-rejection drugs.